Pembrolizumab + Enfortumab vedotin (EV) + Gemcitabine + Cisplatin
Phase 3Completed 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Bladder Cancer
Conditions
Bladder Cancer
Trial Timeline
Apr 21, 2021 → Oct 27, 2025
NCT ID
NCT04700124About Pembrolizumab + Enfortumab vedotin (EV) + Gemcitabine + Cisplatin
Pembrolizumab + Enfortumab vedotin (EV) + Gemcitabine + Cisplatin is a phase 3 stage product being developed by Astellas Pharma for Bladder Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT04700124. Target conditions include Bladder Cancer.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04700124 | Phase 3 | Completed |
Competing Products
20 competing products in Bladder Cancer